A second generation of CDK4/6 inhibitors with a broadened non-catalytic mechanism that also destabilizes cyclin D-CDK6-p21 complexes and complexes containing p27 may overcome resistance mechanisms and improve the efficacy of CDK4/6 inhibitors as anti-cancer therapeutics. The gene discussed is CDKN1A; the disease is cancer.